BAYRY Stock Recent News

Dublin, Jan. 20, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: Bayer AG 2024" report has been added to ResearchAndMarkets.com's offering.

BERLIN--(BUSINESS WIRE)--As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch of one of the largest surveys examining global public sentiment towards transformative technology. The field work was conducted by market research company Ipsos. The Study gleans actionable insights for innovators and leaders who share a responsibility to engage the public. The survey resul.

WHIPPANY, N.J.--(BUSINESS WIRE)--A new survey commissioned by One A Day®, the multivitamin and supplement brand by Bayer rooted in more than 80 years of nutritional science, suggests that societal pressures significantly influence women's decisions to set New Year's resolutions for 2025. While Ditch New Year's Resolution Day (Jan. 17) is thought to be the day when a large number of people abandon their goals for the new year, women are determined to achieve their 2025 resolutions which mainly f.

Registered Dietitian & Nutritionist from Bayer, Kelly Bristow, Shares Expert Tips to Help You Kickstart Your Health and Wellness Journey Registered Dietitian & Nutritionist from Bayer, Kelly Bristow, Shares Expert Tips to Help You Kickstart Your Health and Wellness Journey

A Washington state jury on Tuesday said Bayer must pay $100 million to four people who say they were sickened by exposure to toxic chemicals known as PCBs made by the company's predecessor Monsanto that were used in light fixtures at a Seattle-area school, but found that the company was not liable for injuries alleged by ten others, according to a lawyer for the plaintiffs.

WHIPPANY, N.J.--(BUSINESS WIRE)--On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions underway for key growth drivers darolutamide, finerenone, and elinzanetant. "We are successfully delivering on our ambitious business goals despite significant headwinds. At the same time, the value of our pipeline is growing by accelerating breakthrough innovations,”.

Dublin, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The "Copper Ammonium Carbonate Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering. The copper ammonium carbonate market is expected to grow at a CAGR of 6.69%, reaching a market size of US$13.209 billion in 2030 from US$9.557 billion in 2025. The copper ammonium carbonate market is characterized by its wide application as a fungicide in the agri-business, especially for crops but not limited to wheat, barley, and oats. This compound plays an important part in boosting the yield and quality of crops, which is a major concern considering the rise in food demand from a highly populated world. The advantages associated with this compound have also caused its demand in certain industries. However, there is competition for the market from the green alternatives and a change in perception towards chemical fungicides in turn which will leave the farmers with no options but to evolve to organic farming pract

Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in an interview published on Tuesday.

BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an investigational gadolinium-based contrast agent (GBCA) for use in magnetic resonance imaging (MRI). All QUANTI studies investigated gadoquatrane at a gadolinium dose of 0.04 mmol Gd/kg body weight which represents a gadolinium dose reduction of 60 percent compared to the macrocyclic GBCAs dosed at 0.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for KERENDIA® (finerenone) for the treatment of patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥40%. The submission is based on positive results from the Phase III FINEARTS-HF trial that showed finerenone achieved a statistically significant reduction of the composite of cardiovascular death and t.